Business
BridgeBio Pharma, Inc. Appoints Ronald J. Daniels To Its Board of Directors
President of Johns Hopkins University joins BridgeBio to expand and deepen partnerships with academia PALO ALTO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) --
About this update from Bridgebio Pharma, Inc.
[{"type":"text","content":"President of Johns Hopkins University joins BridgeBio to expand and deepen partnerships with academia\nPALO ALTO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced it has appointed Ronald J. Daniels, president of Johns Hopkins University, to its board of directors, effective immediately.\n “We are so pleased to have Ron join BridgeBio’s board of directors, especially at such a pivotal time in our understanding of genetic diseases,” said BridgeBio CEO and founder Neil Kumar, Ph.D. “We are at the dawn of a new era where companies like BridgeBio are focused on translating promising early-stage research conducted by academic scientists into meaningful medicines for patients. As the president of a university that houses one of the world’s leading academic health centers, Ron is uniquely positioned to help guide BridgeBio as it seeks to bring novel discoveries and treatments to patients.” Serving as the 14th president of Johns Hopkins University since 2009, Daniels has championed interdisciplinary research and innovation initiatives, including the Johns Hopkins Precision Medicine Analytics Platform (PMAP), the Bloomberg-Kimmel Institute for Cancer Immunotherapy, and the recently announced partnership among the Johns Hopkins University School of Medicine, Bloomberg Philanthropies, and The New York Stem Cell Foundation Research Institute. Throughout his tenure at Johns Hopkins University, he has been a vigorous advocate for translating scientific discoveries into novel technologies that directly benefit patients. Daniels has written on the challenges confronting the American biomedical research enterprise and served as chair of the Committee on The Next Generation Initiative of the National Academies of Sciences, Engineering and Medicine in 2017-18. Prior to his role as president of Johns Hopkins, Daniels was provost and professor of law at the University of Pennsylvania and dean and James M. Tory Professor of Law at the University of Toronto. Daniels is a fellow of the American Academy of Arts & Sciences and the American Philosophical Society. BridgeBio is working to revolutionize partnerships between biotech companies and biomedical research institutions, building on the company’s approach of bringing early-stage discoverie...